{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:28:09Z","timestamp":1785803289008,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["182,719"],"award-info":[{"award-number":["182,719"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2022.12.012","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T08:13:08Z","timestamp":1673338388000},"page":"615-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis \u2013 a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-3418","authenticated-orcid":false,"given":"Carmen","family":"Streibel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-9437","authenticated-orcid":false,"given":"Corin C.","family":"Willers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orso","family":"Pusterla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Stranzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Brabandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-5495","authenticated-orcid":false,"given":"Oliver","family":"Bieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-9103","authenticated-orcid":false,"given":"Marion","family":"Curdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-9328","authenticated-orcid":false,"given":"Bettina Sarah","family":"Frauchiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-5280","authenticated-orcid":false,"given":"Insa","family":"Korten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Casaulta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-1571","authenticated-orcid":false,"given":"Philipp","family":"Latzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1741-5221","authenticated-orcid":false,"given":"Elisabeth","family":"Kieninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.12.012_bib0001","unstructured":"Cystic Fibrosis Foundation Patient Registry, Annual Data Report 2020, in Bethesda, Maryland \u00a92021 Cystic Fibrosis Foundation 2020."},{"key":"10.1016\/j.jcf.2022.12.012_bib0002","first-page":"7","article-title":"Disease-modifying drug therapy in cystic fibrosis","volume":"26","author":"Harman","year":"2018","journal-title":"Paediatr Respir Rev"},{"issue":"12","key":"10.1016\/j.jcf.2022.12.012_bib0003","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.012_bib0004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"10212","key":"10.1016\/j.jcf.2022.12.012_bib0005","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2022.12.012_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.012_bib0007","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mrm.26096","article-title":"Matrix pencil decomposition of time-resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion","volume":"77","author":"Bauman","year":"2017","journal-title":"Magn Reson Med"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0008","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/mrm.28947","article-title":"Defect distribution index: a novel metric for functional lung MRI in cystic fibrosis","volume":"86","author":"Valk","year":"2021","journal-title":"Magn Reson Med"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.012_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jcf.2018.10.003","article-title":"Ventilation and perfusion assessed by functional MRI in children with CF: reproducibility in comparison to lung function","volume":"18","author":"Nyilas","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.12.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2021","article-title":"Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis","author":"Campredon","year":"2021","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0011","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of Lumacaftor\u2013Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.012_bib0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2016.12.004","article-title":"Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis","volume":"16","author":"Altes","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0013","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.012_bib0014","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.012_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1164\/rccm.202204-0730ED","article-title":"How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease be Monitored?","volume":"206","author":"Ben-Meir","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.12.012_bib0016","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of Cystic Fibrosis: consensus Guidelines from the Cystic Fibrosis Foundation","volume":"181s","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.012_bib0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.012_bib0018","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"1985","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2022.12.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02686-2020","article-title":"Longitudinal course of clinical lung clearance index in children with cystic fibrosis","volume":"58","author":"Frauchiger","year":"2021","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02398-2021","article-title":"Normative multiple breath washout data in school-aged children corrected for sensor error","volume":"60","author":"Kentgens","year":"2022","journal-title":"Eur Respi J"},{"issue":"8","key":"10.1016\/j.jcf.2022.12.012_bib0021","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0022","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1016\/j.jcf.2022.12.012_bib0023","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/mrm.25697","article-title":"Ultra-fast Steady-State Free Precession Pulse Sequence for Fourier Decomposition Pulmonary MRI","volume":"75","author":"Bauman","year":"2016","journal-title":"Magn Reson Med"},{"issue":"2","key":"10.1016\/j.jcf.2022.12.012_bib0024","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/mrm.28476","article-title":"The impact of segmentation on whole-lung functional MRI quantification: repeatability and reproducibility from multiple human observers and an artificial neural network","volume":"85","author":"Willers","year":"2021","journal-title":"Magn Reson Med"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01464-2017","article-title":"Novel magnetic resonance technique for functional imaging of cystic fibrosis lung disease","volume":"50","author":"Nyilas","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0026","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejrad.2011.02.045","article-title":"Morphologic and functional scoring of cystic fibrosis lung disease using MRI","volume":"81","author":"Eichinger","year":"2012","journal-title":"Eur J Radiol"},{"issue":"12","key":"10.1016\/j.jcf.2022.12.012_bib0027","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1513\/AnnalsATS.201712-967OC","article-title":"Structural and Functional Lung Impairment in Primary Ciliary Dyskinesia. Assessment with Magnetic Resonance Imaging and Multiple Breath Washout in Comparison to Spirometry","volume":"15","author":"Nyilas","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.012_sbref0028","volume":"60","author":"European Respiratory Journal.\u202f","year":"2022"},{"issue":"6","key":"10.1016\/j.jcf.2022.12.012_bib0029","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.chest.2020.12.008","article-title":"The Clinical Use of Lung MRI in Cystic Fibrosis: what, Now, How?","volume":"159","author":"Dournes","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jcf.2022.12.012_bib0030","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/jmri.27030","article-title":"Current state of the art MRI for the longitudinal assessment of cystic fibrosis","volume":"52","author":"Woods","year":"2020","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.jcf.2022.12.012_bib0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1214\/ss\/1032280214","article-title":"Bootstrap confidence intervals","volume":"11","author":"DiCiccio","year":"1996","journal-title":"Statist. Sci."},{"issue":"2","key":"10.1016\/j.jcf.2022.12.012_bib0032","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jcf.2020.12.017","article-title":"Tribulations and (clinical) trials in cystic fibrosis","volume":"20","author":"Cagnina","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.12.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children \u2265 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322014321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:06:56Z","timestamp":1762553216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322014321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199322014321"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis \u2013 a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}